These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 22796458)
1. Targeting BRAFV600E in an inducible murine model of melanoma. Hooijkaas AI; Gadiot J; van der Valk M; Mooi WJ; Blank CU Am J Pathol; 2012 Sep; 181(3):785-94. PubMed ID: 22796458 [TBL] [Abstract][Full Text] [Related]
2. Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in Pten Deken MA; Song JY; Gadiot J; Bins AD; Kroon P; Verbrugge I; Blank CU Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999416 [TBL] [Abstract][Full Text] [Related]
3. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. Knight DA; Ngiow SF; Li M; Parmenter T; Mok S; Cass A; Haynes NM; Kinross K; Yagita H; Koya RC; Graeber TG; Ribas A; McArthur GA; Smyth MJ J Clin Invest; 2013 Mar; 123(3):1371-81. PubMed ID: 23454771 [TBL] [Abstract][Full Text] [Related]
4. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma. Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873 [TBL] [Abstract][Full Text] [Related]
5. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021 [TBL] [Abstract][Full Text] [Related]
6. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969 [TBL] [Abstract][Full Text] [Related]
11. A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. Lelliott EJ; Cullinane C; Martin CA; Walker R; Ramsbottom KM; Souza-Fonseca-Guimaraes F; Abuhammad S; Michie J; Kirby L; Young RJ; Slater A; Lau P; Meeth K; Oliaro J; Haynes N; McArthur GA; Sheppard KE Sci Rep; 2019 Feb; 9(1):1225. PubMed ID: 30718660 [TBL] [Abstract][Full Text] [Related]
12. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875 [TBL] [Abstract][Full Text] [Related]
13. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma. Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238 [TBL] [Abstract][Full Text] [Related]
14. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model. Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822 [TBL] [Abstract][Full Text] [Related]
15. Assaying for BRAF V600E in tissue and blood in melanoma. Panka DJ; Mier JW; Sullivan RJ Methods Mol Biol; 2014; 1102():117-36. PubMed ID: 24258977 [TBL] [Abstract][Full Text] [Related]
16. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Wilmott JS; Long GV; Howle JR; Haydu LE; Sharma RN; Thompson JF; Kefford RF; Hersey P; Scolyer RA Clin Cancer Res; 2012 Mar; 18(5):1386-94. PubMed ID: 22156613 [TBL] [Abstract][Full Text] [Related]
17. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Hong DS; Vence L; Falchook G; Radvanyi LG; Liu C; Goodman V; Legos JJ; Blackman S; Scarmadio A; Kurzrock R; Lizee G; Hwu P Clin Cancer Res; 2012 Apr; 18(8):2326-35. PubMed ID: 22355009 [TBL] [Abstract][Full Text] [Related]
18. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Yang H; Higgins B; Kolinsky K; Packman K; Go Z; Iyer R; Kolis S; Zhao S; Lee R; Grippo JF; Schostack K; Simcox ME; Heimbrook D; Bollag G; Su F Cancer Res; 2010 Jul; 70(13):5518-27. PubMed ID: 20551065 [TBL] [Abstract][Full Text] [Related]
19. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523 [TBL] [Abstract][Full Text] [Related]
20. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Ravnan MC; Matalka MS Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]